Studying Stored Samples From Patients With Localized Prostate Cancer Treated on Clinical Trial NCI-00-C-0154

Data Analysis for 00-C-0154, A Randomized Phase II Study of a PSA-based Vaccine in Patients With Localized Prostate Cancer Receiving Standard Radiotherapy

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00535834

Enrollment

Registered

2007-09-26

Start date

Unknown

Completion date

2011-03-31

Last updated

2012-03-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate Cancer

Keywords

stage I prostate cancer, stage II prostate cancer, stage III prostate cancer, adenocarcinoma of the prostate

Brief summary

RATIONALE: Studying samples of blood in the laboratory from patients before and after treatment may help doctors learn more about the effects of the treatment on cells. PURPOSE: This clinical trial is studying samples collected from patients with localized prostate cancer who received treatment on clinical trial NCI-00-C-0154.

Detailed description

OBJECTIVES: Primary * Evaluate the formation of antibody complexes in serum samples taken before initiation of treatment and after completion of therapy in prostate cancer patients previously enrolled on clinical trial NCI-00-C-0154. * Evaluate immunologic response. Secondary * Clone the underlying tumor antigens discovered through SEREX. OUTLINE: Samples previously collected on clinical trial NCI-00-C-0154 (whole blood, serum, and peripheral mononuclear blood cells) are analyzed for immunologic responses and evidence of formation of anti-tumor antibodies. Western blot is used to detect any evidence of vaccine-induced autoantibody responses. If there is an indication of response, SEREX is used to clone the underlying antigens.

Interventions

PROCEDUREdiagnostic procedure

PROCEDUREmolecular diagnostic method

PROCEDUREprotein expression analysis

Eligibility

Sex/Gender

MALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

DISEASE CHARACTERISTICS: * Diagnosis of localized adenocarcinoma of the prostate * Received treatment on clinical trial NCI-00-C-0154 PATIENT CHARACTERISTICS: * Consented the use of their collected blood cells for future research while enrolled on NCI-00-C-0154 PRIOR CONCURRENT THERAPY: * See Disease Characteristics

Design outcomes

Primary

Measure	Time frame
Immunologic response	—
Incidence of formation of antibody complexes in serum samples taken before initiation of treatment and after completion of therapy by western blot and SEREX	—

Secondary

Measure	Time frame
Cloning of any underlying tumor antigens discovered in this process	—

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026